Search results
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 4 weeks agoCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q1 2024 Earnings Call Transcript May 9, 2024 Catalyst...
Zacks Industry Outlook Highlights Jazz Pharmaceuticals, Catalyst Pharmaceuticals, Aerie...
Zacks via Yahoo Finance· 2 years agoJazz Pharmaceuticals, Catalyst Pharmaceuticals, Aerie Pharmaceuticals, Larimar Therapeutics and...
Catalyst's New CEO Has Big Ideas For The Small Biotech
Investor's Business Daily· 4 weeks agoCatalyst Pharmaceuticals' new Chief Executive, Richard Daly, is no stranger to working at big...
Biotech Leader Plunges On New Offering Of 10 Million Shares
Investor's Business Daily· 5 months agoIBD Sector Leader Catalyst Pharmaceuticals plunged more than 10% on Friday after news that the...
2 Biotech Stocks With Huge Catalysts in 2024
Motley Fool via Yahoo Finance· 5 months agoInvestors seeking stocks that can produce dramatic gains in 2024 can find what they're looking for in the biopharmaceutical industry. Clinical-trial...
2 Big Catalysts Could Send This Already 6.7%-Yielding Dividend Even Higher
Motley Fool· 10 months agoW.P. Carey (NYSE: WPC) stands out for its ability to pay dividends. The diversified REIT currently...
Should You Add Marinus (MRNS) Stock to Your Portfolio Now?
Zacks via Yahoo Finance· 4 months agoMarinus Pharmaceuticals’ MRNS epilepsy medicine, Zalmy (ganaxolone) oral suspension, which was...
Santhera's drug gets US FDA nod for rare muscular dystrophy
Reuters via Yahoo News· 7 months agoShares of Catalyst were up 3.8% in after market trading. Swiss drugmaker Santhera had licensed the...
Why Is Ionis Pharmaceuticals (IONS) Down 5.8% Since Last Earnings Report?
Zacks via Yahoo Finance· 2 years agoIt has been about a month since the last earnings report for Ionis Pharmaceuticals (IONS). Shares...
Esperion (ESPR) Q4 Loss Narrows, Revenues Miss, Stock Down
Zacks via Yahoo Finance· 1 year agoEsperion Therapeutics ESPR incurred a loss per share of 76 cents per share in the fourth quarter of...
